federal_register: 94-9047

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts
94-9047 Determination of Regulatory Review Period for Purposes of Patent Extension; SupprelinRegister; Correction Uncategorized Document The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of June 2, 1992 (57 FR 23237), that announced its determination of the regulatory review period for purposes of patent extension for Supprelin<Register> (histrelin acetate). The document was published with some mathematical errors. The document incorrectly stated, ``FDA has determined that the applicable regulatory review period for Supprelin<Register> is 2,876 days. Of this time, 1,930 days occurred during the testing phase of the regulatory review period, while 946 days occurred during the approval phase.'' It should have stated, ``FDA has determined that the applicable regulatory review period for Supprelin<Register> is 2,878 days. Of this time, 1,931 days occurred during the testing phase of the regulatory review period, while 947 days occurred during the approval phase.'' This document corrects those errors. 1994-04-14 1994 4 https://www.federalregister.gov/documents/1994/04/14/94-9047/determination-of-regulatory-review-period-for-purposes-of-patent-extension-supprelinregister   Health and Human Services Department 221 The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of June 2, 1992 (57 FR 23237), that announced its determination of the regulatory review period for purposes of patent extension for Supprelin<Register>...

Links from other tables